keyword
MENU ▼
Read by QxMD icon Read
search

Nocturnal polyuria

keyword
https://www.readbyqxmd.com/read/29099160/evaluation-of-the-occurrence-and-diagnose-definitions-for-nocturnal-polyuria-in-spinal-cord-injured-patients-during-rehabilitation
#1
Annick Viaene, Marie-Astrid Denys, An-Sofie Goessaert, Jana Claeys, Ann Raes, Saskia Roggeman, Karel Everaert
BACKGROUND: Little is known about the occurrence of nocturnal polyuria in spinal cord injured (SCI) patients and the definitions which are preferable in this population. AIM: To determine the occurrence of nocturnal polyuria (NP) in spinal cord injured patients during in-patient rehabilitation in the Ghent University Hospital. To study the influence of different time periods (daytime, bed rest and sleep) on the accuracy of the existing diagnose definitions for NP specifically for this type of patients...
November 3, 2017: European Journal of Physical and Rehabilitation Medicine
https://www.readbyqxmd.com/read/29057582/an-exploratory-pilot-study-with-copeptin-as-a-biomarker-for-individualizing-treatment-for-nocturnal-polyuria
#2
Elke Bruneel, An-Sofie Goessaert, Marie-Astrid Denys, Kristian V Juul, Jens P Nørgaard, Karel Everaert
OBJECTIVE: The aim of the present study was to investigate the use of random copeptin concentrations as possible biomarkers for the differential diagnosis of nocturnal polyuria (NP). METHODS: In all, 111 patients with and without nocturia were enrolled in the study. Patients with a neurogenic bladder and/or those who had undergone bladder or urethral surgery were excluded from the study. All patients completed a 72-hour frequency-volume chart and a renal function profile...
October 23, 2017: Lower Urinary Tract Symptoms
https://www.readbyqxmd.com/read/29055129/desmopressin-for-treating-nocturia-in-men
#3
REVIEW
Julia Han, Jae Hung Jung, Caitlin J Bakker, Mark H Ebell, Philipp Dahm
BACKGROUND: Nocturia is the bothersome symptom of awakening one or more times per night to void. Desmopressin is a commonly used medication for treating nocturia. OBJECTIVES: To assess the effects of desmopressin as compared to other interventions in the treatment of nocturia in men. SEARCH METHODS: We performed a comprehensive search of medical literature with no restrictions on the language of publication or publication status. The date of the latest search of all databases was August 2017...
October 21, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29048257/desmopressin-acetate-nasal-spray-for-adults-with-nocturia
#4
Joshua A Cohn, Casey G Kowalik, W Stuart Reynolds, Melissa R Kaufman, Douglas F Milam, Roger R Dmochowski, Alan J Wein
Nocturia impacts 70% of individuals over age 70 years. Nocturnal polyuria is present in up to 88% of adults with nocturia, however, treatment options for reducing nighttime urine production have historically been limited to behavioral modification and off label use of timed diuretics and desmopressin. Noctiva(TM) (desmopressin acetate nasal spray, DANS, Serenity Pharmaceuticals, LLC) is a novel formulation of desmopressin approved by the Food and Drug Administration for the treatment of nocturia due to nocturnal polyuria in March 2017...
October 30, 2017: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/29026531/nocturia-consequences-classification-and-management
#5
REVIEW
Noam D Fine, Jeffrey P Weiss, Alan J Wein
Nocturia is a widespread condition that can negatively impact quality of sleep and overall health. This condition is multifactorial in nature and is best approached through the analysis of frequency volume charts. Through these charts, clinicians may classify each individual case of nocturia into one of four distinct categories: global polyuria, nocturnal polyuria, reduced bladder capacity, and mixed. Treatments should then be tailored to each individual based upon the category of their nocturia. In some cases, appropriate therapy will consist of behavioral modification techniques or addressing underlying systemic diseases...
2017: F1000Research
https://www.readbyqxmd.com/read/28984060/a-practical-approach-to-the-management-of-nocturia
#6
Matthias Oelke, Stefan De Wachter, Marcus J Drake, Antonella Giannantoni, Mike Kirby, Susan Orme, Jonathan Rees, Philip van Kerrebroeck, Karel Everaert
AIM: To raise awareness on nocturia disease burden and to provide simplified aetiologic evaluation and related treatment pathways. METHODS: A multidisciplinary group of nocturia experts developed practical advice and recommendations based on the best available evidence supplemented by their own experiences. RESULTS: Nocturia is defined as the need to void ≥1 time during the sleeping period of the night. Clinically relevant nocturia (≥2 voids per night) affects 2%-18% of those aged 20-40 years, rising to 28%-62% for those aged 70-80 years...
October 5, 2017: International Journal of Clinical Practice
https://www.readbyqxmd.com/read/28815743/pathophysiology-of-nocturnal-lower-urinary-tract-symptoms-in-older-patients-with-urinary-incontinence
#7
Marie-Astrid Denys, Veerle Decalf, Candy Kumps, Mirko Petrovic, An-Sofie Goessaert, Karel Everaert
OBJECTIVES: To explore the mismatch between functional bladder capacity and nocturnal urine production, and to study the pathophysiology of an increased nocturnal urine production in older patients with urinary incontinence. METHODS: The present prospective observational study included adults aged ≥65 years with urinary incontinence. Participants completed questionnaires, frequency volume charts and renal function profiles. The nocturnal lower urinary tract symptom index was defined as nocturnal urine output/maximum voided volume; the nocturnal polyuria index as nocturnal/24 h urine output...
November 2017: International Journal of Urology: Official Journal of the Japanese Urological Association
https://www.readbyqxmd.com/read/28747281/transcutaneous-electrical-nerve-stimulation-in-children-with-monosymptomatic-nocturnal-enuresis-a-randomized-double-blind-placebo-controlled-study
#8
Cecilie Siggaard Jørgensen, Konstantinos Kamperis, Luise Borch, Britt Borg, Søren Rittig
PURPOSE: In a third of all children with monosymptomatic nocturnal enuresis their condition is refractory to first line treatments. Transcutaneous electrical nerve stimulation has been documented to be efficacious in children with daytime incontinence. We investigated the effect of transcutaneous electrical nerve stimulation in children with monosymptomatic nocturnal enuresis without nocturnal polyuria. MATERIALS AND METHODS: Children with monosymptomatic nocturnal enuresis (3 or more wet nights per week) and no nocturnal polyuria were randomized to treatment with active or sham transcutaneous electrical nerve stimulation involving 1-hour sessions twice daily for 10 weeks in a double-blind design...
September 2017: Journal of Urology
https://www.readbyqxmd.com/read/28718163/incidence-and-management-of-lower-urinary-tract-symptoms-after-urethral-stricture-repair
#9
REVIEW
Amanda S J Chung, Kurt A McCammon
Lower urinary tract symptoms (LUTS) after urethral stricture repair are not uncommon. Urgency has been reported in 40% of men and urge incontinence in 12% of men after anterior urethroplasty. De novo urgency and urge incontinence is seen in 9 and 5% of men, respectively, after urethroplasty. Once a complication of urethroplasty (such as recurrent urethral stricture or diverticulum) has been excluded as a cause, evaluation of LUTS in such patients should focus on differentiating bladder dysfunction (overactive bladder, underactive bladder), from other outlet obstruction (such as benign prostatic obstruction), dysfunctional voiding, or medical causes (such as nocturnal polyuria)...
September 2017: Current Urology Reports
https://www.readbyqxmd.com/read/28714288/tolterodine-treatment-of-women-with-overactive-bladder-syndrome-comparison-of-night-time-and-daytime-dosing-for-nocturia
#10
Ko-Hsin Tsai, Sheng-Mou Hsiao, Ho-Hsiung Lin
AIM: We aimed to clarify the impact of night-time dosing with tolterodine extended release (ER) on nocturia. METHODS: The bladder diaries, urodynamic studies, and medical records of female patients with overactive bladder syndrome who were diagnosed between January 2005 and December 2015, and treated with tolterodine ER 4 mg once per day (night-time or daytime dosing) for 12 weeks in the urogynecology outpatient clinics of two tertiary referral centers were reviewed retrospectively...
July 16, 2017: Journal of Obstetrics and Gynaecology Research
https://www.readbyqxmd.com/read/28691778/a-different-way-to-study-frequency-volume-charts-in-patients-with-nocturia
#11
Marie-Astrid Denys, An-Sofie Goessaert, Brecht Dejaeghere, Veerle Decalf, Piet Hoebeke, Karel Everaert
BACKGROUND: Nocturia results from a mismatch between bladder capacity and nocturnal urine production (NUP), which is determined with a frequency volume charts (FVC). AIM: This is the first study that aimed to describe variations in nocturia severity and its associated factors by evaluating FVCs per single 24 h-period. METHODS: This was a post-hoc analysis of patients who completed a 72 h-FVC in prospective, observational studies. The nocturnal polyuria index (NPi ) was defined as the ratio of nocturnal and 24 h urine output...
July 10, 2017: Neurourology and Urodynamics
https://www.readbyqxmd.com/read/28666669/medical-treatment-of-nocturia-in-men-with-lower-urinary-tract-symptoms-systematic-review-by-the-european-association-of-urology-guidelines-panel-for-male-lower-urinary-tract-symptoms
#12
REVIEW
Vasileios I Sakalis, Markos Karavitakis, Dina Bedretdinova, Thorsten Bach, J L H Ruud Bosch, Mauro Gacci, Christian Gratzke, Thomas R Herrmann, Stephan Madersbacher, Charalampos Mamoulakis, Kari A O Tikkinen, Stavros Gravas, Marcus J Drake
CONTEXT: The treatment of nocturia is a key challenge due to the multi-factorial pathophysiology of the symptom and the disparate outcome measures used in research. OBJECTIVE: To assess and compare available therapy options for nocturia, in terms of symptom severity and quality of life. EVIDENCE ACQUISITION: Medical databases (Embase, Medline, Cochrane Systematic Reviews, Cochrane Central) were searched with no date restriction. Comparative studies were included which studied adult men with nocturia as the primary presentation and lower urinary tract symptoms including nocturia or nocturnal polyuria...
November 2017: European Urology
https://www.readbyqxmd.com/read/28634090/evaluation-of-the-effect-of-3-month-bladder-basic-advice-in-children-with-monosymptomatic-nocturnal-enuresis
#13
Marcin Tkaczyk, Michał Maternik, Anna Krakowska, Agnieszka Wosiak, Monika Miklaszewska, Katarzyna Zachwieja, Dariusz Runowski, Anna Jander, Dariusz Ratajczak, Agata Korzeniecka-Kozyrska, Izabella Mader-Wołyńska, Katarzyna Kiliś-Pstrusińska
INTRODUCTION: Advice (BBA) into the standards of patients' care in both monosymptomatic and non-monosymptomatic nocturnal enuresis. Although the idea of this recommendation was clear and reflects clinical experience, duration and efficacy have not been definitely established. Recent data have demonstrated the lack of efficacy of BBA and a fierce discussion has ensued. The present study was aimed to assess the efficacy of BBA in a group of previously untreated children with primary monosymptomatic nocturnal enuresis (MNE)...
June 1, 2017: Journal of Pediatric Urology
https://www.readbyqxmd.com/read/28560762/low-dose-desmopressin-and-tolterodine-combination-therapy-for-treating-nocturia-in-women-with-overactive-bladder-a-double-blind-randomized-controlled-study
#14
Eric S Rovner, Kyle Raymond, Eugene Andruczyk, Kristian V Juul
OBJECTIVE: Evaluation of safety and efficacy of desmopressin/tolterodine combination therapy in women. METHODS: This double-blind, randomized, proof-of-concept study enrolled 106 patients (≥18 years), with overactive bladder (OAB) and nocturia, with ≥2 nocturnal voids, receiving a 3-month once-daily combination (desmopressin 25 µg, orally-disintegrating tablets [ODT]/tolterodine 4 mg [Detrol® LA]; n = 49) or monotherapy (tolterodine 4 mg/placebo ODT; n = 57)...
May 31, 2017: Lower Urinary Tract Symptoms
https://www.readbyqxmd.com/read/28479837/pharmaceutical-approval-update
#15
Mary Choy
Brodalumab (Siliq) for moderate-to-severe plaque psoriasis in adults; telotristat ethyl (Xermelo) for carcinoid syndrome diarrhea in combination with somatostatin analogue therapy in adults; and desmopressin acetate (Noctiva) for adults with nocturnal polyuria.
May 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28479240/fesoterodine-for-the-treatment-of-nocturnal-urgency-in-patients-with-overactive-bladder-syndrome-an-analysis-of-responders-and-nonresponders
#16
Johnathan A Khusid, Jeffrey P Weiss, Martin O Carlsson, Erin K Mangan
PURPOSE: A recent study demonstrated improvement in nocturnal urgency in patients with overactive bladder when treated with fesoterodine. In the current study we aimed to determine which bladder diary parameters predict the response to fesoterodine in these patients. MATERIALS AND METHODS: Patients with nocturnal urgency completed a 2-week, single-blind placebo run-in followed by 1:1 double-blind randomization to 12 weeks of fesoterodine or placebo. We analyzed bladder diary parameter changes from baseline to week 12, including the actual number of night voids (total number of nocturia episodes), maximum voided volume, nocturnal bladder capacity, Nocturnal Bladder Capacity Index (NBCi) (actual number of night voids - nocturnal urine volume/maximum voided volume - 1), nocturnal urine volume, the nocturia index (nocturnal urine volume/maximum voided volume) and the nocturnal polyuria index (nocturnal urine volume/24-hour volume)...
November 2017: Journal of Urology
https://www.readbyqxmd.com/read/28457803/evaluation-of-urinary-aquaporin-2-and-plasma-copeptin-as-biomarkers-of-effectiveness-of-desmopressin-acetate-for-the-treatment-of-monosymptomatic-nocturnal-enuresis
#17
Taichi Hara, Yoshiyuki Ohtomo, Amane Endo, Shinichi Niijima, Masato Yasui, Toshiaki Shimizu
PURPOSE: Desmopressin is a synthetic V2 specific analogue of antidiuretic hormone (arginine vasopressin) that is widely used as first line treatment for monosymptomatic nocturnal enuresis. However, no biomarkers to predict desmopressin effectiveness have yet been established. Because arginine vasopressin is unstable, we prospectively measured the major urine concentration factor aquaporin 2 and serum copeptin (as a surrogate marker for vasopressin) in patients with monosymptomatic nocturnal enuresis, and evaluated whether they are useful for predicting desmopressin treatment outcome...
April 28, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28456542/dietary-sodium-restriction-reduces-nocturnal-urine-volume-and-nocturnal-polyuria-index-in-renal-allograft-recipients-with-nocturnal-polyuria
#18
Yoshinaga Okumura, Kanae Asai, Takashi Kobayashi, Hitomi Miyata, Yukari Tanaka, Yoshiyuki Okada, Kaoru Sakai, Tomomi Kamba, Hidemi Tsuji, Kenichiro Shide, Kazuaki Nagashima, Motoko Yanagita, Nobuya Inagaki, Osamu Ogawa, Hiromitsu Negoro
OBJECTIVE: To investigate whether sodium restriction alters the nocturnal urine volume (NUV) and the ratio of NUV to 24-hour urine of renal allograft recipients (RARs). MATERIALS AND METHODS: This prospective, single-center study analyzed 38 of the 59 RARs who were followed up for more than 6 months in our hospital. All patients underwent 3 sessions of dietary counseling performed by a board-certified dietitian. Before and after these 3 sessions, 24-hour urine samples were collected, along with voiding frequency volume charts...
August 2017: Urology
https://www.readbyqxmd.com/read/28418465/nocturnal-polyuria-drug-approved
#19
Rebecca Voelker
No abstract text is available yet for this article.
April 18, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28295650/daily-salt-intake-is-an-independent-risk-factor-for-pollakiuria-and-nocturia
#20
Tomohiro Matsuo, Yasuyoshi Miyata, Hideki Sakai
OBJECTIVE: To clarify the relationships between daily salt intake and lower urinary tract symptoms. METHODS: A cross-sectional clinical study was carried out with 728 patients. Spot urine samples were collected to evaluate estimated daily salt intake. The patients were divided into two groups based on mean salt intake (9.2 g/day). Their urinary condition was evaluated using the Core Lower Urinary Tract Symptoms score and 3-day frequency volume charts. The influence of salt intake on lower urinary tract symptoms was investigated using multivariate logistic regression analysis...
March 14, 2017: International Journal of Urology: Official Journal of the Japanese Urological Association
keyword
keyword
110213
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"